NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of bevacizumab for relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. If, after doing this, organisations still wish to consider bevacizumab for relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, they should follow the advice on rational local decision‑making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.
NICE will review the position at any point if the company indicates that it wishes to make a full submission.
© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not‑for‑profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.